Veru Inc. (NASDAQ:VERU - Get Free Report) was the target of unusually large options trading activity on Tuesday. Investors bought 8,511 call options on the stock. This is an increase of approximately 500% compared to the typical daily volume of 1,418 call options.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Perceptive Advisors LLC boosted its holdings in shares of Veru by 26.5% during the 2nd quarter. Perceptive Advisors LLC now owns 7,063,277 shares of the company's stock valued at $5,942,000 after acquiring an additional 1,478,578 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Veru by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 2,940,140 shares of the company's stock worth $2,261,000 after purchasing an additional 131,720 shares during the period. State Street Corp lifted its stake in shares of Veru by 4.3% in the 3rd quarter. State Street Corp now owns 2,072,065 shares of the company's stock worth $1,593,000 after purchasing an additional 84,483 shares during the period. PVG Asset Management Corp raised its stake in Veru by 13.1% during the 3rd quarter. PVG Asset Management Corp now owns 636,970 shares of the company's stock worth $490,000 after acquiring an additional 73,815 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in Veru by 1,718.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 443,782 shares of the company's stock worth $373,000 after acquiring an additional 419,374 shares during the period. 47.16% of the stock is owned by hedge funds and other institutional investors.
Shares of Veru stock opened at $1.09 on Wednesday. Veru has a 52-week low of $0.36 and a 52-week high of $1.92. The stock has a market capitalization of $159.55 million, a price-to-earnings ratio of -3.89 and a beta of -0.53. The company has a fifty day moving average of $0.70 and a 200-day moving average of $0.80.
Veru (NASDAQ:VERU - Get Free Report) last posted its quarterly earnings results on Monday, December 16th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. Veru had a negative net margin of 223.85% and a negative return on equity of 92.88%. On average, equities research analysts forecast that Veru will post -0.26 earnings per share for the current fiscal year.
Several analysts have recently issued reports on the stock. Oppenheimer reissued an "outperform" rating and issued a $5.00 price target on shares of Veru in a research report on Tuesday, November 5th. HC Wainwright reaffirmed a "buy" rating and set a $3.00 price objective on shares of Veru in a research note on Thursday, January 2nd.
View Our Latest Stock Report on VERU
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Veru, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.
While Veru currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.